WisdomTree BioRevolution Fund
WDNA
Chicago Board Options Exchange- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 250 West 34th Street, 3rd Floor New York NY United States of America 10119
- IPO Date
- Jun 3, 2021
- CIK
- 0001350487
- Website
- wisdomtree.com
- Similar Companies
- Business
- WisdomTree BioRevolution Fund (WDNA) is an exchange-traded fund that tracks the WisdomTree BioRevolution Index, providing investors with targeted exposure to developed market companies significantly transformed by advancements in genetics and biotechnology. The fund employs a modified equal-weighting methodology, focusing on firms deriving at least 50% of revenue from BioRevolution sectors including human health, consumer products, agriculture and food, materials chemicals and energy, and biological machines and interfaces; top holdings include Intellia Therapeutics Inc., uniQure NV, CRISPR Therapeutics AG, Ginkgo Bioworks Holdings Inc., and Stoke Therapeutics Inc., alongside established names such as Eli Lilly and Co., Novartis AG, and Moderna Inc. Launched on June 3, 2021, and managed by WisdomTree, Inc., headquartered in New York, the ETF primarily targets U.S. investors with geographic allocations heavily weighted toward the United States (approximately 80%), followed by Switzerland, Germany, Denmark, and the United Kingdom. WDNA complements core equity portfolios by offering multi-sector exposure to innovative growth megatrends in genetics, biotechnology, and related fields, emphasizing companies with strong growth characteristics amid risks such as intense competition, rapid product obsolescence, intellectual property challenges, and regulatory changes. The fund maintains total assets under management of approximately $2.2 million as of mid-2025, with an expense ratio of 0.45%, a semi-annual reconstitution and rebalance process overseen by an Index Committee, and no options trading availability. In recent developments, parent company WisdomTree, Inc. announced and completed the acquisition of Ceres Partners, LLC—a leading U.S. farmland investment manager—for $275 million in cash plus a potential $225 million earn-out in July and October 2025, respectively, marking WisdomTree's strategic entry into private asset markets and enhancing its offerings in agriculture-adjacent real assets that align thematically with WDNA's agribusiness and food sector focus. This transaction positions WisdomTree as a category leader in U.S. farmland, diversifying beyond ETFs into high-growth areas like solar, AI data infrastructure, and water opportunities, while remaining accretive to earnings from day one. No specific product launches, partnerships, or reorganizations directly impacting WDNA have been reported in the last 1-2 years, though the fund continues to evolve through its index methodology to capture expanding biotechnology innovations.